Frontiers in oncology · 2026
Comparison of long-term prognoses between 3D-printed template-guided and conventional freehand interstitial brachytherapy for locally advanced cervical cancer: a single-center retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miao Jun-Jun, Zhang Xu-Yu, Zhang Yong-Xia, Gao Lei, Zhao Lu-Jun
Аннотация
OBJECTIVE: Conventional freehand three-dimensional interstitial brachytherapy (F-3DIB) for locally advanced cervical cancer (LACC) is limited by suboptimal dose distribution and operator dependency. This study aimed to evaluate the long-term survival and safety benefits of 3D-printed template-guided interstitial brachytherapy (3D-PTIB).
METHODS: This retrospective single-center cohort study included 300 patients with FIGO IIB-IVA LACC who underwent brachytherapy between January 2021 and June 2022. The median follow-up time was 36.2 months (range: 34-41). Follow-up data were collected between January 2024 and June 2025, ensuring adequate follow-up for survival assessment. Patients were divided into 3D-PTIB and F-3DIB groups. Propensity score matching was used to balance baseline characteristics, resulting in a matched cohort of 240 patients. The outcomes assessed included 3-year overall survival (OS), progression-free survival (PFS), local control (LC), dosimetric parameters, and late toxicities.
RESULTS: The 3D-PTIB group exhibited significantly better 3-year OS (76.7% vs. 66.2%, HR = 0.69, p = 0.02) and LC (90.0% vs. 78.3%, HR = 0.47, p = 0.01) than the F-3DIB group. A trend toward improved 3-year PFS was also observed (70.8% vs. 62.3%, HR = 0.73, p = 0.05). Notably, the 3D-PTIB group achieved an 11.7% absolute improvement in local control (90.0% vs. 78.3%). A post hoc power analysis indicated that the study had approximately 80% power (α = 0.05, two-sided) to detect the observed hazard ratio of 0.69 for OS in the matched cohort. Dosimetric advantages included a significantly greater HR-CTV D90 (87.5 ± 3.2 Gy vs. 82.1 ± 4.8 Gy, p < 0.001) and reduced rectal D2 cc (64.5 ± 5.1 Gy vs. 72.3 ± 6.7 Gy, p < 0.001). Clinically, the incidence of ≥ grade 3 radiation proctitis was significantly lower in the 3D-PTIB group (4.2% vs. 11.7%, p = 0.008).
CONCLUSION: 3D-printed template-guided interstitial brachytherapy significantly improves intermediate- to long-term survival and reduces late toxicity in LACC patients, particularly high-risk patients with a tumor diameter > 4 cm or parametrial invasion, highlighting its potential as a superior alternative to conventional freehand interstitial brachytherapy.
METHODS: This retrospective single-center cohort study included 300 patients with FIGO IIB-IVA LACC who underwent brachytherapy between January 2021 and June 2022. The median follow-up time was 36.2 months (range: 34-41). Follow-up data were collected between January 2024 and June 2025, ensuring adequate follow-up for survival assessment. Patients were divided into 3D-PTIB and F-3DIB groups. Propensity score matching was used to balance baseline characteristics, resulting in a matched cohort of 240 patients. The outcomes assessed included 3-year overall survival (OS), progression-free survival (PFS), local control (LC), dosimetric parameters, and late toxicities.
RESULTS: The 3D-PTIB group exhibited significantly better 3-year OS (76.7% vs. 66.2%, HR = 0.69, p = 0.02) and LC (90.0% vs. 78.3%, HR = 0.47, p = 0.01) than the F-3DIB group. A trend toward improved 3-year PFS was also observed (70.8% vs. 62.3%, HR = 0.73, p = 0.05). Notably, the 3D-PTIB group achieved an 11.7% absolute improvement in local control (90.0% vs. 78.3%). A post hoc power analysis indicated that the study had approximately 80% power (α = 0.05, two-sided) to detect the observed hazard ratio of 0.69 for OS in the matched cohort. Dosimetric advantages included a significantly greater HR-CTV D90 (87.5 ± 3.2 Gy vs. 82.1 ± 4.8 Gy, p < 0.001) and reduced rectal D2 cc (64.5 ± 5.1 Gy vs. 72.3 ± 6.7 Gy, p < 0.001). Clinically, the incidence of ≥ grade 3 radiation proctitis was significantly lower in the 3D-PTIB group (4.2% vs. 11.7%, p = 0.008).
CONCLUSION: 3D-printed template-guided interstitial brachytherapy significantly improves intermediate- to long-term survival and reduces late toxicity in LACC patients, particularly high-risk patients with a tumor diameter > 4 cm or parametrial invasion, highlighting its potential as a superior alternative to conventional freehand interstitial brachytherapy.